Abstract

目的研究白血病干细胞(LSC)相关抗原CD34、CD38、CD123、CD96和TIM-3在t(8;21)急性髓系白血病(AML)中的表达及预后意义。方法采集2015年10月至2018年4月北京大学人民医院收治的47例初诊t(8;21)AML患者的骨髓标本,采用流式细胞术检测LSC相关膜表面抗原CD34、CD38、CD123、CD96和TIM-3的表达,分析其与复发的关系。结果47例t(8;21)AML患者中,CD34+CD38−、CD34+CD38−CD123+、CD34+CD38−CD96+、CD34+CD38−TIM-3+细胞在有核细胞中比例的中位数分别为2.37%、0.24%、0.27%、0.06%;CD34+CD38−、CD34+CD38−CD123+、CD34+CD38−CD96+和CD34+CD38−TIM-3+细胞比例与诱导治疗1个疗程缓解率无明显相关性(P值均>0.05);CD34+CD38−、CD34+CD38−CD123+和CD34+CD38−CD96+细胞比例高的患者较比例低的患者具有更高的2年累积复发(CIR)率(P值分别为0.049、0.030、0.045),而CD34+CD38−TIM-3+细胞的比例对CIR无明显影响(P>0.05);CD34+CD38−细胞比例及微小残留病(MRD)水平是影响患者CIR的独立预后因素(HR=6.9,95%CI 1.3~37.4,P=0.025;HR=11.1,95%CI 1.2~99.2,P=0.031)。结论不同的LSC相关抗原在t(8;21)AML中的预后意义不同,初诊骨髓有核细胞中高比例的CD34+CD38−以及CD34+CD38−CD123+和CD34+CD38−CD96+细胞可能与t(8;21)AML患者的复发有关。

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.